Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Tencent Share Purchase Rights Makes HUYA Compelling Stock into 2020

Tech Pulse: Virus Drives Traffic to Tencent Games, 'Impossible Meat' Trend Growing in China

Daily Tech Pulse: Smartphone Supply Chain Disruptions and Building Brand Loyalty in Crisis

Huya Live Streaming IPO: Fairly Valued Amid Lacklustre Segment Sentiment (Part 3)

Huya (虎牙) Live Streaming IPO: Granular Differences Between Huya and Douyu (斗鱼) (Part 2)

Huya Live Streaming IPO: Fast Growing Industry but Competition Is Intense (Part 1)

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>Huya, a leading live streaming player in China, announced share placement of USD 550 million after market close on April 3rd. In this insight, we will look at recent developments of Huya and score the deal in our ECM Framework.</p>

Huya, a leading live streaming player in China, announced share placement of USD 550 million after market close on April 3rd. In this insight, we will look at recent developments of Huya and score the deal in our ECM Framework.

Huya Placement: Best Performing Live Streaming Stock but Beware Douyu Is Catching Up